View graph of relations


    Professor Lorraine Martin holds a BSc and PhD in Biochemistry and a Masters of Medical Science in Clinical Laboratory Medicine.  At the outset of her career, Professor Martin played a pivotal role in a joint programme between Queen's University Belfast and the biotechnology company behind Dolly the cloned sheep, PPL Therapeutics plc, Edinburgh and was heavily involved in the Phase II clinical trials of a transgenic human protein, known as alpha1 antrypsin in cystic fibrosis (CF).  Professor Martin was then funded by a Sir Henry Wellcome Innovative Award to develop tools for the real-time monitoring and subsequent inhibition of intracellular proteolysis before taking up her academic appointment in the School of Pharmacy, Queen's University Belfast. 

    Within the Biomolecular Sciences Research Group, Professor Martin has continued to focus on active proteases and their role in health and disease which includes the profiling, delineation and inhibition of proteases involved in infection and inflammation in chronic airways diseases, such as CF and chronic obstructive pulmonary disease (COPD). A major strategic programme of work, funded by sequential grants from the Cystic Fibrosis Trust, is the targeting of channel activating proteases (CAPs) as a means to regulate the epithelial sodium channel (ENaC), dysregulation of which contributes to airways dehydration in CF, and has included an important drug discovery element of significant impact.  A second programme of work has been the commercial exploitation of patented QUB ProteaseTag™ technology which evolved from a Proof of Concept (Invest Northern Ireland) project with further support provided by the MRC.  In August 2013, Professor Martin co-founded and became CEO of ProAxsis Ltd and in September 2013, Professor Martin won the highly competitive NISP Connect 25K Award (Northern Ireland Science Park; now INVENT, Catalyst Inc.).   Professor Martin went on to secure significant investment from QUBIS Ltd and a prestigious external (London-based), internationally recognised company, NetScientific plc. as well as a Horizon 2020 SME instrument award (2014).  She continues to contribute to the strategic development of ProAxsis and is also actively involved in supporting a range of other entrepreneurial activities as well as the development of productive research collaborations with UK industry and global pharma.  In November 2016 Professor Martin was awarded the Queen's University Vice-Chancellor's Research Impact Prize in recognition of the success and impact of these commercialisation and innovation activities. 

    Professor Martin has published widely in internationally recognised peer-reviewed journals and currently holds 4 patents. She has presented her work both nationally and internationally and has held funding from the like of BBSRC, MRC, Prostate Cancer Charity, Cystic Fibrosis Trust, UK and the Cystic Fibrosis Foundation, USA. In addition, Professor Martin has secured significant European funding (€7.7 M) through the INTERREG Va programme (SEUPB) to build cross-border capacity in COPD research. BREATH (Borders and REgions Airways Training Hub) is a 5-year collaborative programme between QUB, Dundalk Institute of Technology and the University of the West of Scotland and funds 22 full-time researchers across the 3 partners.  

    Willingness to take PhD students


    PhD projects

    Open to PhD applications in the field of ion channel modulation, proteases as potential biomarkers and therapeutics targets, infection and inflammation, chronic diseases, to include respiratory diseases and chronic wounds.

    View all

    Frequent Journals

    • Pediatric Pulmonology

      ISSNs: 8755-6863, 1099-0496

      Additional searchable ISSN (Electronic): 1099-0496

      Wiley-Liss Inc.

      Scopus rating (2018): CiteScore 2.38 SJR 1.15 SNIP 0.927


    • Thorax

      ISSNs: 0040-6376, 1468-3296

      BMJ Publishing Group

      Scopus rating (2018): CiteScore 4.63 SJR 3.697 SNIP 2.383


    • Journal of Cystic Fibrosis

      ISSNs: 1569-1993

      Elsevier Inc.

      Scopus rating (2018): CiteScore 2.88 SJR 1.57 SNIP 1.245


    • Journal of Pharmacy and Pharmacology

      ISSNs: 0022-3573

      Additional searchable ISSN (Electronic): 2042-7158

      Pharmaceutical Press

      Scopus rating (2018): CiteScore 2.32 SJR 0.568 SNIP 0.772


    • European Respiratory Journal

      ISSNs: 0903-1936

      Additional searchable ISSN (Electronic): 1399-3003


      Scopus rating (2018): CiteScore 4.82 SJR 3.925 SNIP 2.397


    View all »

    View all

    View all

    Contribution to conference papers, events and activities

    ID: 19802